Attention Deficit Disorder With Hyperactivity — Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17
Citation(s)
A Phase II Study to Assess the Safety, Tolerability and Efficacy of SPD503 Administered to Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)